Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Nov;34(5):377–395. doi: 10.1111/j.1365-2125.1992.tb05647.x

Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

B K Park 1, M Pirmohamed 1, N R Kitteringham 1
PMCID: PMC1381466  PMID: 1467132

Full text

PDF
377

Images in this article

386Figure 1
on p.386

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramson M., Littlejohn G. O. Hepatic reactions to nifedipine. Med J Aust. 1985 Jan 7;142(1):47–48. doi: 10.5694/j.1326-5377.1985.tb113285.x. [DOI] [PubMed] [Google Scholar]
  2. Ammus S., Yunis A. A. Drug-induced red cell dyscrasias. Blood Rev. 1989 Jun;3(2):71–82. doi: 10.1016/0268-960x(89)90001-5. [DOI] [PubMed] [Google Scholar]
  3. Ascherl M., Eyer P., Kampffmeyer H. Formation and disposition of nitrosochloramphenicol in rat liver. Biochem Pharmacol. 1985 Oct 15;34(20):3755–3763. doi: 10.1016/0006-2952(85)90242-4. [DOI] [PubMed] [Google Scholar]
  4. Babany G., Mallat A., Zafrani E. S., Saint-Marc Girardin M. F., Carcone B., Dhumeaux D. Chronic liver disease after low daily doses of amiodarone. Report of three cases. J Hepatol. 1986;3(2):228–232. doi: 10.1016/s0168-8278(86)80031-9. [DOI] [PubMed] [Google Scholar]
  5. Bahri A. K., Chiang C. S., Timbrell J. A. Acetylhydrazine hepatotoxicity. Toxicol Appl Pharmacol. 1981 Sep 30;60(3):561–569. doi: 10.1016/0041-008x(81)90343-4. [DOI] [PubMed] [Google Scholar]
  6. Baisch J. M., Weeks T., Giles R., Hoover M., Stastny P., Capra J. D. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N Engl J Med. 1990 Jun 28;322(26):1836–1841. doi: 10.1056/NEJM199006283222602. [DOI] [PubMed] [Google Scholar]
  7. Batchelor J. R., Welsh K. I., Tinoco R. M., Dollery C. T., Hughes G. R., Bernstein R., Ryan P., Naish P. F., Aber G. M., Bing R. F. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet. 1980 May 24;1(8178):1107–1109. doi: 10.1016/s0140-6736(80)91554-8. [DOI] [PubMed] [Google Scholar]
  8. Beaune P., Dansette P. M., Mansuy D., Kiffel L., Finck M., Amar C., Leroux J. P., Homberg J. C. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A. 1987 Jan;84(2):551–555. doi: 10.1073/pnas.84.2.551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bell S. J., Pichler W. J. Penicillin-allergic patients react to penicillin-modified "self". Allergy. 1989 Apr;44(3):199–203. doi: 10.1111/j.1398-9995.1989.tb02262.x. [DOI] [PubMed] [Google Scholar]
  10. Bensen W. G., Moore N., Tugwell P., D'Souza M., Singal D. P. HLA antigens and toxic reactions to sodium aurothiomalate in patients with rheumatoid arthritis. J Rheumatol. 1984 Jun;11(3):358–361. [PubMed] [Google Scholar]
  11. Beutler E. Disorders due to enzyme defects in the red blood cell. Adv Metab Disord. 1972;60:131–160. doi: 10.1016/b978-0-12-027306-5.50010-3. [DOI] [PubMed] [Google Scholar]
  12. Beutler E. Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med. 1991 Jan 17;324(3):169–174. doi: 10.1056/NEJM199101173240306. [DOI] [PubMed] [Google Scholar]
  13. Blomgren S. E., Condemi J. J., Vaughan J. H. Procainamide-induced lupus erythematosus. Clinical and laboratory observations. Am J Med. 1972 Mar;52(3):338–348. doi: 10.1016/0002-9343(72)90021-6. [DOI] [PubMed] [Google Scholar]
  14. Bourdi M., Larrey D., Nataf J., Bernuau J., Pessayre D., Iwasaki M., Guengerich F. P., Beaune P. H. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest. 1990 Jun;85(6):1967–1973. doi: 10.1172/JCI114660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Britt B. A., Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J. 1970 Jul;17(4):293–315. doi: 10.1007/BF03004694. [DOI] [PubMed] [Google Scholar]
  16. Bugawan T. L., Angelini G., Larrick J., Auricchio S., Ferrara G. B., Erlich H. A. A combination of a particular HLA-DP beta allele and an HLA-DQ heterodimer confers susceptibility to coeliac disease. Nature. 1989 Jun 8;339(6224):470–473. doi: 10.1038/339470a0. [DOI] [PubMed] [Google Scholar]
  17. Böttiger L. E., Furhoff A. K., Holmberg L. Drug-induced blood dyscrasias. A ten-year material from the Swedish Adverse Drug Reaction Committee. Acta Med Scand. 1979;205(6):457–461. [PubMed] [Google Scholar]
  18. Chadwick D., Shaw M. D., Foy P., Rawlins M. D., Turnbull D. M. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry. 1984 Jun;47(6):642–644. doi: 10.1136/jnnp.47.6.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chan H. L., Stern R. S., Arndt K. A., Langlois J., Jick S. S., Jick H., Walker A. M. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990 Jan;126(1):43–47. [PubMed] [Google Scholar]
  20. Chaplin S. Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part I. Adverse Drug React Acute Poisoning Rev. 1986 Summer;5(2):97–136. [PubMed] [Google Scholar]
  21. Clark J. A., Zimmerman H. J., Tanner L. A. Labetalol hepatotoxicity. Ann Intern Med. 1990 Aug 1;113(3):210–213. doi: 10.7326/0003-4819-113-3-210. [DOI] [PubMed] [Google Scholar]
  22. Clarke J. B., Neftel K., Kitteringham N. R., Park B. K. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol. 1991;95(4):369–375. doi: 10.1159/000235475. [DOI] [PubMed] [Google Scholar]
  23. Coleman M. D., Breckenridge A. M., Park B. K. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol. 1989 Oct;28(4):389–395. doi: 10.1111/j.1365-2125.1989.tb03517.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Coulter D. M., Edwards I. R. Mianserin and agranulocytosis in New Zealand. Lancet. 1990 Sep 29;336(8718):785–787. doi: 10.1016/0140-6736(90)93248-n. [DOI] [PubMed] [Google Scholar]
  25. Cribb A. E., Grant D. M., Miller M. A., Spielberg S. P. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J Pharmacol Exp Ther. 1991 Dec;259(3):1241–1246. [PubMed] [Google Scholar]
  26. DeLeve L. D., Kaplowitz N. Importance and regulation of hepatic glutathione. Semin Liver Dis. 1990 Nov;10(4):251–266. doi: 10.1055/s-2008-1040481. [DOI] [PubMed] [Google Scholar]
  27. Delamere J. P., Jobson S., Mackintosh L. P., Wells L., Walton K. W. Penicillamine-induced myasthenia in rheumatoid arthritis: its clinical and genetic features. Ann Rheum Dis. 1983 Oct;42(5):500–504. doi: 10.1136/ard.42.5.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Dequeker J., Van Wanghe P., Verdickt W. A systematic survey of HLA-A,B,C and D antigens and drug toxicity in rheumatoid arthritis. J Rheumatol. 1984 Jun;11(3):282–286. [PubMed] [Google Scholar]
  29. Diez R. A. HLA-B27 and agranulocytosis by levamisole. Immunol Today. 1990 Aug;11(8):270–270. doi: 10.1016/0167-5699(90)90109-m. [DOI] [PubMed] [Google Scholar]
  30. Dreifuss F. E., Langer D. H., Moline K. A., Maxwell J. E. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology. 1989 Feb;39(2 Pt 1):201–207. doi: 10.1212/wnl.39.2.201. [DOI] [PubMed] [Google Scholar]
  31. Dreifuss F. E., Santilli N., Langer D. H., Sweeney K. P., Moline K. A., Menander K. B. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987 Mar;37(3):379–385. doi: 10.1212/wnl.37.3.379. [DOI] [PubMed] [Google Scholar]
  32. Dujovne C. A., Chan C. H., Zimmerman H. J. Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med. 1967 Oct 12;277(15):785–788. doi: 10.1056/NEJM196710122771503. [DOI] [PubMed] [Google Scholar]
  33. Edwards C. R., Drury P., Penketh A., Damluji S. A. Successful reintroduction of captopril following neutropenia. Lancet. 1981 Mar 28;1(8222):723–723. doi: 10.1016/s0140-6736(81)91998-x. [DOI] [PubMed] [Google Scholar]
  34. Elis A., Lishner M., Lang R., Ravid M. Agranulocytosis associated with enalapril. DICP. 1991 May;25(5):461–462. doi: 10.1177/106002809102500502. [DOI] [PubMed] [Google Scholar]
  35. Emery P., Panayi G. S., Huston G., Welsh K. I., Mitchell S. C., Shah R. R., Idle J. R., Smith R. L., Waring R. H. D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol. 1984 Oct;11(5):626–632. [PubMed] [Google Scholar]
  36. Evans D. A., Bullen M. F., Houston J., Hopkins C. A., Vetters J. M. Antinuclear factor in rapid and slow acetylator patients treated with isoniazid. J Med Genet. 1972 Mar;9(1):53–56. doi: 10.1136/jmg.9.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ferraccioli G., Peri F., Nervetti A., Ambanelli U., Savi M. Toxicity due to remission inducing drugs in rheumatoid arthritis. Association with HLA-B35 and Cw4 antigens. J Rheumatol. 1986 Feb;13(1):65–68. [PubMed] [Google Scholar]
  38. Fischer V., Haar J. A., Greiner L., Lloyd R. V., Mason R. P. Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis. Mol Pharmacol. 1991 Nov;40(5):846–853. [PubMed] [Google Scholar]
  39. Gerson W. T., Fine D. G., Spielberg S. P., Sensenbrenner L. L. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood. 1983 May;61(5):889–893. [PubMed] [Google Scholar]
  40. Godeau P., Aubert M., Imbert J. C., Herreman G. Lupus érythemateux disséminé et taux d'isoniazide actif. Etude de 47 observations. Ann Med Interne (Paris) 1973 Mar;124(3):181–186. [PubMed] [Google Scholar]
  41. Gonzalez F. J. The molecular biology of cytochrome P450s. Pharmacol Rev. 1988 Dec;40(4):243–288. [PubMed] [Google Scholar]
  42. Gordin F. M., Simon G. L., Wofsy C. B., Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984 Apr;100(4):495–499. doi: 10.7326/0003-4819-100-4-495. [DOI] [PubMed] [Google Scholar]
  43. Gran J. T., Husby G., Thorsby E. HLA DR antigens and gold toxicity. Ann Rheum Dis. 1983 Feb;42(1):63–66. doi: 10.1136/ard.42.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Guffy M. M., Goeken N. E., Burns C. P. Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis. Arch Intern Med. 1984 Aug;144(8):1687–1688. doi: 10.1001/archinte.144.8.1687. [DOI] [PubMed] [Google Scholar]
  45. Guillaume J. C., Roujeau J. C., Revuz J., Penso D., Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol. 1987 Sep;123(9):1166–1170. [PubMed] [Google Scholar]
  46. Hakala M., van Assendelft A. H., Ilonen J., Jalava S., Tiilikainen A. Association of different HLA antigens with various toxic effects of gold salts in rheumatoid arthritis. Ann Rheum Dis. 1986 Mar;45(3):177–182. doi: 10.1136/ard.45.3.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Hamdy R. C., Murnane B., Perera N., Woodcock K., Koch I. M. The pharmacokinetics of benoxaprofen in elderly subjects. Eur J Rheumatol Inflamm. 1982;5(2):69–75. [PubMed] [Google Scholar]
  48. Healy S. J., Heffron J. J., Lehane M., Bradley D. G., Johnson K., McCarthy T. V. Diagnosis of susceptibility to malignant hyperthermia with flanking DNA markers. BMJ. 1991 Nov 16;303(6812):1225–1228. doi: 10.1136/bmj.303.6812.1225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Heffron J. J. Malignant hyperthermia: biochemical aspects of the acute episode. Br J Anaesth. 1988 Feb;60(3):274–278. doi: 10.1093/bja/60.3.274. [DOI] [PubMed] [Google Scholar]
  50. Hensen E. J., Claas F. H., Vermeer B. J. Drug-dependent binding of circulating antibodies in drug-induced toxic epidermal necrolysis. Lancet. 1981 Jul 18;2(8238):151–152. doi: 10.1016/s0140-6736(81)90332-9. [DOI] [PubMed] [Google Scholar]
  51. Homberg J. C., Stelly N., Andreis I., Abuaf N., Saadoun F., Andre J. A new antimitochondria antibody (anti-M6) in iproniazid-induced hepatitis. Clin Exp Immunol. 1982 Jan;47(1):93–102. [PMC free article] [PubMed] [Google Scholar]
  52. Hoorntje S. J., Kallenberg C. G., Weening J. J., Donker A. J., The T. H., Hoedemaeker P. J. Immune-complex glomerulopathy in patients treated with captopril. Lancet. 1980 Jun 7;1(8180):1212–1215. doi: 10.1016/s0140-6736(80)91677-3. [DOI] [PubMed] [Google Scholar]
  53. Hoorntje S. J., Weening J. J., Kallenberg C. G., Prins E. J., Donker A. J. Serum-sickness-like syndrome with membranous glomerulopathy in patient on captopril. Lancet. 1979 Dec 15;2(8155):1297–1297. doi: 10.1016/s0140-6736(79)92303-1. [DOI] [PubMed] [Google Scholar]
  54. Houwerzijl J., De Gast G. C., Nater J. P., Esselink M. T., Nieweg H. O. Lymphocyte-stimulation tests and patch tests to carbamazepine hypersensitivity. Clin Exp Immunol. 1977 Aug;29(2):272–277. [PMC free article] [PubMed] [Google Scholar]
  55. Iaizzo P. A., Klein W., Lehmann-Horn F. Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs. Pflugers Arch. 1988 Jun;411(6):648–653. doi: 10.1007/BF00580861. [DOI] [PubMed] [Google Scholar]
  56. Idle J. R. Is environmental carcinogenesis modulated by host polymorphism? Mutat Res. 1991 Apr;247(2):259–266. doi: 10.1016/0027-5107(91)90021-f. [DOI] [PubMed] [Google Scholar]
  57. Johnson D. A., Cattau E. L., Jr, Kuritsky J. N., Zimmerman H. J. Liver involvement in the sulfone syndrome. Arch Intern Med. 1986 May;146(5):875–877. [PubMed] [Google Scholar]
  58. Joyce D. A., Day R. O., Murphy B. R. The pharmacokinetics of albumin conjugates of D-penicillamine in humans. Drug Metab Dispos. 1991 Mar-Apr;19(2):309–311. [PubMed] [Google Scholar]
  59. Kaplowitz N., Aw T. Y., Simon F. R., Stolz A. Drug-induced hepatotoxicity. Ann Intern Med. 1986 Jun;104(6):826–839. doi: 10.7326/0003-4819-104-6-826. [DOI] [PubMed] [Google Scholar]
  60. Kappus H., Remmer H. Irreversible protein binding of [14-C]imipramine with rat and human liver microsomes. Biochem Pharmacol. 1975 May 15;24(10):1079–1084. doi: 10.1016/0006-2952(75)90193-8. [DOI] [PubMed] [Google Scholar]
  61. Kassahun K., Farrell K., Abbott F. Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab Dispos. 1991 Mar-Apr;19(2):525–535. [PubMed] [Google Scholar]
  62. Kay A. G. Myelotoxicity of D-penicillamine. Ann Rheum Dis. 1979 Jun;38(3):232–236. doi: 10.1136/ard.38.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Kay A. G. Myelotoxicity of gold. Br Med J. 1976 May 22;1(6020):1266–1268. doi: 10.1136/bmj.1.6020.1266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Kenna J. G., Neuberger J., Williams R. Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology. 1988 Nov-Dec;8(6):1635–1641. doi: 10.1002/hep.1840080627. [DOI] [PubMed] [Google Scholar]
  65. Kitteringham N. R., Lambert C., Maggs J. L., Colbert J., Park B. K. A comparative study of the formation of chemically reactive drug metabolites by human liver microsomes. Br J Clin Pharmacol. 1988 Jul;26(1):13–21. doi: 10.1111/j.1365-2125.1988.tb03358.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Krag E. The normal gastric and duodenal rugage. Radiographic findings in non-dyspeptic young persons. Acta Med Scand. 1967 Jul;182(1):1–4. [PubMed] [Google Scholar]
  67. Kubo M., Hostetler K. Y. Diethylaminoethoxyhexestrol inhibition of purified rat liver lysosomal phospholipase A1: role of drug binding to substrate. J Pharmacol Exp Ther. 1987 Jan;240(1):88–92. [PubMed] [Google Scholar]
  68. Lafaye P., Lapresle C. Fixation of penicilloyl groups to albumin and appearance of anti-penicilloyl antibodies in penicillin-treated patients. J Clin Invest. 1988 Jul;82(1):7–12. doi: 10.1172/JCI113603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Lahita R., Kluger J., Drayer D. E., Koffler D., Reidenberg M. M. Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide. N Engl J Med. 1979 Dec 20;301(25):1382–1385. doi: 10.1056/NEJM197912203012506. [DOI] [PubMed] [Google Scholar]
  70. Lambert C., Park B. K., Kitteringham N. R. Activation of mianserin and its metabolites by human liver microsomes. Biochem Pharmacol. 1989 Sep 1;38(17):2853–2858. doi: 10.1016/0006-2952(89)90441-3. [DOI] [PubMed] [Google Scholar]
  71. Larrey D., Berson A., Habersetzer F., Tinel M., Castot A., Babany G., Lettéron P., Freneaux E., Loeper J., Dansette P. Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant. Hepatology. 1989 Aug;10(2):168–173. doi: 10.1002/hep.1840100208. [DOI] [PubMed] [Google Scholar]
  72. Larrey D., Funck-Brentano C., Breil P., Vitaux J., Theodore C., Babany G., Pessayre D. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol. 1983 Mar 15;32(6):1063–1068. doi: 10.1016/0006-2952(83)90626-3. [DOI] [PubMed] [Google Scholar]
  73. Larrey D., Tinel M., Pessayre D. Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem Pharmacol. 1983 May 1;32(9):1487–1493. doi: 10.1016/0006-2952(83)90470-7. [DOI] [PubMed] [Google Scholar]
  74. Lieberman J. A., Yunis J., Egea E., Canoso R. T., Kane J. M., Yunis E. J. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry. 1990 Oct;47(10):945–948. doi: 10.1001/archpsyc.1990.01810220061007. [DOI] [PubMed] [Google Scholar]
  75. Lieh-Lai M. W., Sarnaik A. P., Newton J. F., Miceli J. N., Fleischmann L. E., Hook J. B., Kauffman R. E. Metabolism and pharmacokinetics of acetaminophen in a severely poisoned young child. J Pediatr. 1984 Jul;105(1):125–128. doi: 10.1016/s0022-3476(84)80376-5. [DOI] [PubMed] [Google Scholar]
  76. Lockridge O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther. 1990;47(1):35–60. doi: 10.1016/0163-7258(90)90044-3. [DOI] [PubMed] [Google Scholar]
  77. López J. R., Alamo L., Caputo C., Wikinski J., Ledezma D. Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle Nerve. 1985 Jun;8(5):355–358. doi: 10.1002/mus.880080502. [DOI] [PubMed] [Google Scholar]
  78. MOESCHLIN S., WAGNER K. [Agranulocytosis due to the occurrence of leukocyte-agglutinins; pyramidon and cold agglutinins]. Acta Haematol. 1952 Jul-Aug;8(1-2):29–41. doi: 10.1159/000204146. [DOI] [PubMed] [Google Scholar]
  79. MacLennan D. H., Duff C., Zorzato F., Fujii J., Phillips M., Korneluk R. G., Frodis W., Britt B. A., Worton R. G. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature. 1990 Feb 8;343(6258):559–561. doi: 10.1038/343559a0. [DOI] [PubMed] [Google Scholar]
  80. Manyan D. R., Arimura G. K., Yunis A. A. Comparative metabolic effects of chloramphenicol analogues. Mol Pharmacol. 1975 Sep;11(5):520–527. [PubMed] [Google Scholar]
  81. Mickelson J. R., Gallant E. M., Litterer L. A., Johnson K. M., Rempel W. E., Louis C. F. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem. 1988 Jul 5;263(19):9310–9315. [PubMed] [Google Scholar]
  82. Miller L. G., Prichard J. G. Current issues in NSAID therapy. Prim Care. 1990 Sep;17(3):589–601. [PubMed] [Google Scholar]
  83. Mitchell J. R., Zimmerman H. J., Ishak K. G., Thorgeirsson U. P., Timbrell J. A., Snodgrass W. R., Nelson S. D. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976 Feb;84(2):181–192. doi: 10.7326/0003-4819-84-2-181. [DOI] [PubMed] [Google Scholar]
  84. Miyauchi H., Hosokawa H., Akaeda T., Iba H., Asada Y. T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells. Arch Dermatol. 1991 Jun;127(6):851–855. [PubMed] [Google Scholar]
  85. Morgan M. Y., Reshef R., Shah R. R., Oates N. S., Smith R. L., Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut. 1984 Oct;25(10):1057–1064. doi: 10.1136/gut.25.10.1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Moses L. E., Mosteller F. Institutional differences in Postoperative death rates. Commentary on some of the findings of the National Halothane Study. JAMA. 1968 Feb 12;203(7):492–494. [PubMed] [Google Scholar]
  87. Nash D. T., Feer T. D. Hepatic injury possibly induced by verapamil. JAMA. 1983 Jan 21;249(3):395–396. [PubMed] [Google Scholar]
  88. Neftel K. A., Woodtly W., Schmid M., Frick P. G., Fehr J. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):721–723. doi: 10.1136/bmj.292.6522.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Nelson S. D., Mitchell J. R., Snodgrass W. R., Timbrell J. A. Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. J Pharmacol Exp Ther. 1978 Sep;206(3):574–585. [PubMed] [Google Scholar]
  90. Pachoula-Papasteriades C., Boki K., Varla-Leftherioti M., Kappos-Rigatou I., Fostiropoulos G., Economidou J. HLA-A,-B, and -DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA. Dis Markers. 1986 Jun;4(1-2):35–41. [PubMed] [Google Scholar]
  91. Park B. K., Coleman J. W., Kitteringham N. R. Drug disposition and drug hypersensitivity. Biochem Pharmacol. 1987 Mar 1;36(5):581–590. [PubMed] [Google Scholar]
  92. Park B. K., Kitteringham N. R. Drug-protein conjugation and its immunological consequences. Drug Metab Rev. 1990;22(1):87–144. doi: 10.3109/03602539008991445. [DOI] [PubMed] [Google Scholar]
  93. Park B. K. Metabolic basis of adverse drug reactions. J R Coll Physicians Lond. 1986 Jul;20(3):195–200. [PMC free article] [PubMed] [Google Scholar]
  94. Perry H. M., Jr, Tan E. M., Carmody S., Sakamoto A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med. 1970 Jul;76(1):114–125. [PubMed] [Google Scholar]
  95. Pessayre D., Larrey D. Acute and chronic drug-induced hepatitis. Baillieres Clin Gastroenterol. 1988 Apr;2(2):385–422. doi: 10.1016/0950-3528(88)90009-7. [DOI] [PubMed] [Google Scholar]
  96. Pirmohamed M., Graham A., Roberts P., Smith D., Chadwick D., Breckenridge A. M., Park B. K. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol. 1991 Dec;32(6):741–749. [PMC free article] [PubMed] [Google Scholar]
  97. Pirmohamed M., Kitteringham N. R., Park B. K. Idiosyncratic reactions to antidepressants: a review of the possible mechanisms and predisposing factors. Pharmacol Ther. 1992;53(1):105–125. doi: 10.1016/0163-7258(92)90046-3. [DOI] [PubMed] [Google Scholar]
  98. Pisciotta A. V. Drug-induced agranulocytosis. Peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev. 1990 Dec;4(4):226–237. doi: 10.1016/0268-960x(90)90002-a. [DOI] [PubMed] [Google Scholar]
  99. Pisciotta A. V. Immune and toxic mechanisms in drug-induced agranulocytosis. Semin Hematol. 1973 Oct;10(4):279–310. [PubMed] [Google Scholar]
  100. Pohl L. R. Drug-induced allergic hepatitis. Semin Liver Dis. 1990 Nov;10(4):305–315. doi: 10.1055/s-2008-1040486. [DOI] [PubMed] [Google Scholar]
  101. Pohl L. R., Kenna J. G., Satoh H., Christ D., Martin J. L. Neoantigens associated with halothane hepatitis. Drug Metab Rev. 1989;20(2-4):203–217. doi: 10.3109/03602538909103537. [DOI] [PubMed] [Google Scholar]
  102. Pohl L. R., Satoh H., Christ D. D., Kenna J. G. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol. 1988;28:367–387. doi: 10.1146/annurev.pa.28.040188.002055. [DOI] [PubMed] [Google Scholar]
  103. Pons C., Dansette P. M., Amar C., Jaouen M., Wolf C. R., Gregeois J., Homberg J. C., Mansuy D. Detection of human hepatitis anti-liver kidney microsomes (LKM2) autoantibodies on rat liver sections is predominantly due to reactivity with rat liver P-450 IIC11. J Pharmacol Exp Ther. 1991 Dec;259(3):1328–1334. [PubMed] [Google Scholar]
  104. ROSENBLUM L. E., KORN R. J., ZIMMERMAN H. J. Hepatocellular jaundice as a complication of iproniazid therapy. Arch Intern Med. 1960 Apr;105:583–593. doi: 10.1001/archinte.1960.00270160081010. [DOI] [PubMed] [Google Scholar]
  105. Raviglione M. C., Pablos-Mendez A., Battan R. Clinical features and management of severe dermatological reactions to drugs. Drug Saf. 1990 Jan-Feb;5(1):39–64. doi: 10.2165/00002018-199005010-00005. [DOI] [PubMed] [Google Scholar]
  106. Rawlins M. D. Spontaneous reporting of adverse drug reactions. II: Uses. Br J Clin Pharmacol. 1988 Jul;26(1):7–11. doi: 10.1111/j.1365-2125.1988.tb03357.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Reed D. J. Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol. 1990;30:603–631. doi: 10.1146/annurev.pa.30.040190.003131. [DOI] [PubMed] [Google Scholar]
  108. Rettenmeier A. W., Prickett K. S., Gordon W. P., Bjorge S. M., Chang S. L., Levy R. H., Baillie T. A. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Drug Metab Dispos. 1985 Jan-Feb;13(1):81–96. [PubMed] [Google Scholar]
  109. Rieder M. J., Shear N. H., Kanee A., Tang B. K., Spielberg S. P. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther. 1991 Jan;49(1):13–17. doi: 10.1038/clpt.1991.3. [DOI] [PubMed] [Google Scholar]
  110. Rieder M. J., Uetrecht J., Shear N. H., Cannon M., Miller M., Spielberg S. P. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med. 1989 Feb 15;110(4):286–289. doi: 10.7326/0003-4819-110-4-286. [DOI] [PubMed] [Google Scholar]
  111. Riley R. J., Cribb A. E., Spielberg S. P. Glutathione transferase mu deficiency is not a marker for predisposition to sulphonamide toxicity. Biochem Pharmacol. 1991 Jul 15;42(3):696–698. doi: 10.1016/0006-2952(91)90334-2. [DOI] [PubMed] [Google Scholar]
  112. Roden D. M., Reele S. B., Higgins S. B., Wilkinson G. R., Smith R. F., Oates J. A., Woosley R. L. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol. 1980 Sep;46(3):463–468. doi: 10.1016/0002-9149(80)90016-8. [DOI] [PubMed] [Google Scholar]
  113. Rodman J. S., Deutsch D. J., Gutman S. I. Methyldopa Hepatitis. A report of six cases and review of the literature. Am J Med. 1976 Jun;60(7):941–948. doi: 10.1016/0002-9343(76)90564-7. [DOI] [PubMed] [Google Scholar]
  114. Roujeau J. C., Guillaume J. C., Fabre J. P., Penso D., Fléchet M. L., Girre J. P. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990 Jan;126(1):37–42. doi: 10.1001/archderm.126.1.37. [DOI] [PubMed] [Google Scholar]
  115. Roujeau J. C., Huynh T. N., Bracq C., Guillaume J. C., Revuz J., Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol. 1987 Sep;123(9):1171–1173. [PubMed] [Google Scholar]
  116. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol. 1985 Oct;13(4):623–635. doi: 10.1016/s0190-9622(85)70207-1. [DOI] [PubMed] [Google Scholar]
  117. Russell G. I., Bing R. F., Jones J. A., Thurston H., Swales J. D. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype. Q J Med. 1987 Oct;65(246):845–852. [PubMed] [Google Scholar]
  118. SCOTT E. M. The relation of diaphorase of human erythrocytes to inheritance of methemoglobinemia. J Clin Invest. 1960 Jul;39:1176–1179. doi: 10.1172/JCI104131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Satoh H., Martin B. M., Schulick A. H., Christ D. D., Kenna J. G., Pohl L. R. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc Natl Acad Sci U S A. 1989 Jan;86(1):322–326. doi: 10.1073/pnas.86.1.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Saurat J. H. Cutaneous manifestations of graft-versus-host disease. Int J Dermatol. 1981 May;20(4):249–256. doi: 10.1111/j.1365-4362.1981.tb04329.x. [DOI] [PubMed] [Google Scholar]
  121. Scheffner D., König S., Rauterberg-Ruland I., Kochen W., Hofmann W. J., Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia. 1988 Sep-Oct;29(5):530–542. doi: 10.1111/j.1528-1157.1988.tb03757.x. [DOI] [PubMed] [Google Scholar]
  122. Scherak O., Smolen J. S., Mayr W. R., Mayrhofer F., Kolarz G., Thumb N. J. HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis. J Rheumatol. 1984 Oct;11(5):610–614. [PubMed] [Google Scholar]
  123. Schöpf E., Stühmer A., Rzany B., Victor N., Zentgraf R., Kapp J. F. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991 Jun;127(6):839–842. doi: 10.1001/archderm.1991.01680050083008. [DOI] [PubMed] [Google Scholar]
  124. Seidegård J., Pero R. W., Markowitz M. M., Roush G., Miller D. G., Beattie E. J. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis. 1990 Jan;11(1):33–36. doi: 10.1093/carcin/11.1.33. [DOI] [PubMed] [Google Scholar]
  125. Seidegård J., Vorachek W. R., Pero R. W., Pearson W. R. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7293–7297. doi: 10.1073/pnas.85.19.7293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Shah R. R., Oates N. S., Idle J. R., Smith R. L., Lockhart J. D. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):295–299. doi: 10.1136/bmj.284.6312.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Shear N. H., Spielberg S. P. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest. 1988 Dec;82(6):1826–1832. doi: 10.1172/JCI113798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Shear N. H., Spielberg S. P. In vitro evaluation of a toxic metabolite of sulfadiazine. Can J Physiol Pharmacol. 1985 Nov;63(11):1370–1372. doi: 10.1139/y85-225. [DOI] [PubMed] [Google Scholar]
  129. Sherlock S. The spectrum of hepatotoxicity due to drugs. Lancet. 1986 Aug 23;2(8504):440–444. doi: 10.1016/s0140-6736(86)92144-6. [DOI] [PubMed] [Google Scholar]
  130. Singal D. P., Reid B., Green D., D'Souza M., Bensen W. G., Buchanan W. W. Polymorphism of major histocompatibility complex extended haplotypes bearing HLA-DR3 in patients with rheumatoid arthritis with gold induced thrombocytopenia or proteinuria. Ann Rheum Dis. 1990 Aug;49(8):582–586. doi: 10.1136/ard.49.8.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Spielberg S. P. Acetaminophen toxicity in human lymphocytes in vitro. J Pharmacol Exp Ther. 1980 May;213(2):395–398. [PubMed] [Google Scholar]
  132. Spielberg S. P., Gordon G. B., Blake D. A., Goldstein D. A., Herlong H. F. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med. 1981 Sep 24;305(13):722–727. doi: 10.1056/NEJM198109243051302. [DOI] [PubMed] [Google Scholar]
  133. Spielberg S. P. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Fed Proc. 1984 May 15;43(8):2308–2313. [PubMed] [Google Scholar]
  134. Spielberg S. P., Shear N. H., Cannon M., Hutson N. J., Gunderson K. In-vitro assessment of a hypersensitivity syndrome associated with sorbinil. Ann Intern Med. 1991 May 1;114(9):720–724. doi: 10.7326/0003-4819-114-9-720. [DOI] [PubMed] [Google Scholar]
  135. Stein K. M., Schlappner O. L., Heaton C. L., Decherd J. W. Demonstration of basal cell immunofluorescence in drug-induced toxic epidermal necrolysis. Br J Dermatol. 1972 Mar;86(3):246–252. doi: 10.1111/j.1365-2133.1972.tb02224.x. [DOI] [PubMed] [Google Scholar]
  136. Stern R. S., Chan H. L. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol. 1989 Aug;21(2 Pt 1):317–322. doi: 10.1016/s0190-9622(89)70176-6. [DOI] [PubMed] [Google Scholar]
  137. Stockman A., Zilko P. J., Major G. A., Tait B. D., Property D. N., Mathews J. D., Hannah M. C., McCluskey J., Muirden K. D. Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine. J Rheumatol. 1986 Apr;13(2):269–273. [PubMed] [Google Scholar]
  138. Strom B. L., Carson J. L., Halpern A. C., Schinnar R., Snyder E. S., Shaw M., Tilson H. H., Joseph M., Dai W. S., Chen D. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol. 1991 Jun;127(6):831–838. [PubMed] [Google Scholar]
  139. Søeberg B., Sumerska T., Binns R. M., Balfour B. M. Contact sensitivity in the pig. III. Induction by intralymphatic infusion of DNP-conjugated cell membranes and soluble proteins, free DNFB and some small molecular weight derivatives. Int Arch Allergy Appl Immunol. 1978;57(6):481–487. [PubMed] [Google Scholar]
  140. Thompson J. S., Herbick J. M., Klassen L. W., Severson C. D., Overlin V. L., Blaschke J. W., Silverman M. A., Vogel C. L. Studies on levamisole--induced agranulocytosis. Blood. 1980 Sep;56(3):388–396. [PubMed] [Google Scholar]
  141. Timbrell J. A. Drug hepatotoxicity. Br J Clin Pharmacol. 1983 Jan;15(1):3–14. doi: 10.1111/j.1365-2125.1983.tb01456.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Timbrell J. A., Facchini V., Harland S. J., Mansilla-Tinoco R. Hydralazine-induced lupus: is there a toxic metabolic pathway? Eur J Clin Pharmacol. 1984;27(5):555–559. doi: 10.1007/BF00556891. [DOI] [PubMed] [Google Scholar]
  143. Timbrell J. A., Wright J. M., Baillie T. A. Monoacetylhydrazine as a metabolite of isoniazid in man. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):602–608. doi: 10.1002/cpt1977225part1602. [DOI] [PubMed] [Google Scholar]
  144. Treleaven J., Barrett J. Drugs and the bone marrow. Br J Hosp Med. 1990 Oct;44(4):245–250. [PubMed] [Google Scholar]
  145. Uetrecht J. Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions. Crit Rev Toxicol. 1990;20(4):213–235. doi: 10.3109/10408449009089863. [DOI] [PubMed] [Google Scholar]
  146. Uetrecht J., Zahid N., Shear N. H., Biggar W. D. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther. 1988 Apr;245(1):274–279. [PubMed] [Google Scholar]
  147. Vincent P. C. Drug-induced aplastic anaemia and agranulocytosis. Incidence and mechanisms. Drugs. 1986 Jan;31(1):52–63. doi: 10.2165/00003495-198631010-00004. [DOI] [PubMed] [Google Scholar]
  148. Waldhauser L., Uetrecht J. Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis. Drug Metab Dispos. 1991 Mar-Apr;19(2):354–359. [PubMed] [Google Scholar]
  149. Weber W. W., Hein D. W., Litwin A., Lower G. M., Jr Relationship of acetylator status to isoniazid toxicity, lupus erythematosus, and bladder cancer. Fed Proc. 1983 Nov;42(14):3086–3097. [PubMed] [Google Scholar]
  150. Wiencke J. K., Kelsey K. T., Lamela R. A., Toscano W. A., Jr Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res. 1990 Mar 1;50(5):1585–1590. [PubMed] [Google Scholar]
  151. Williamson J., Chopin J. M. Adverse reactions to prescribed drugs in the elderly: a multicentre investigation. Age Ageing. 1980 May;9(2):73–80. doi: 10.1093/ageing/9.2.73. [DOI] [PubMed] [Google Scholar]
  152. Wooley P. H., Griffin J., Panayi G. S., Batchelor J. R., Welsh K. I., Gibson T. J. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med. 1980 Aug 7;303(6):300–302. doi: 10.1056/NEJM198008073030602. [DOI] [PubMed] [Google Scholar]
  153. Woosley R. L., Drayer D. E., Reidenberg M. M., Nies A. S., Carr K., Oates J. A. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med. 1978 May 25;298(21):1157–1159. doi: 10.1056/NEJM197805252982101. [DOI] [PubMed] [Google Scholar]
  154. Worlledge S. M. Immune drug-induced haemolytic anemias. Semin Hematol. 1969 Apr;6(2):181–200. [PubMed] [Google Scholar]
  155. Yan A., Davis P. Gold induced marrow suppression: a review of 10 cases. J Rheumatol. 1990 Jan;17(1):47–51. [PubMed] [Google Scholar]
  156. Zakrzewska J. M., Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10, 11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol. 1988 Jul;82(1):110–115. doi: 10.1016/0091-6749(88)90059-0. [DOI] [PubMed] [Google Scholar]
  157. Zimmerman H. J. Update of hepatotoxicity due to classes of drugs in common clinical use: non-steroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin Liver Dis. 1990 Nov;10(4):322–338. doi: 10.1055/s-2008-1040488. [DOI] [PubMed] [Google Scholar]
  158. Zone J., Ward J., Boyce E., Schupbach C. Penicillamine-induced pemphigus. JAMA. 1982 May 21;247(19):2705–2707. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES